Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (151-160 of 282) with videos related to

Pageof 29
Sort By:
The Journal of Infectious Diseases|December 1, 2019
Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)Juan Tiraboschi, Arkaitz Imaz, Saye Khoo, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2015
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spotsAdeniyi Olagunju, Alieu Amara, Catriona Waitt, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2008
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patientsJosé Moltó, José R Santos, Nuria Pérez-Alvarez, et al.
Vox Sanguinis|March 9, 2026
Pre-exposure prophylaxis use in blood donors in EnglandJaid Debrah, Claire Reynolds, Victoria Maddox, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Antiviral Therapy|May 4, 2005
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13)Alina Bergshoeff, David Burger, Corrien Verweij, et al.
British Journal of Clinical Pharmacology|November 28, 2015
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and childrenAlessandro Schipani, Henry Pertinez, Rachel Mlota, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 30, 2009
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic studySonia Rodríguez-Nóvoa, Pablo Labarga, Vincent Soriano, et al.
Journal of the International AIDS Society|November 14, 2014
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implantKimberly Scarsi, Mohammed Lamorde, Kristin Darin, et al.
Pageof 29

Showing results (151-160 of 282) with videos related to

Sort By:
Pageof 29
The Journal of Infectious Diseases|December 1, 2019
Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)Juan Tiraboschi, Arkaitz Imaz, Saye Khoo, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2015
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spotsAdeniyi Olagunju, Alieu Amara, Catriona Waitt, et al.
Antimicrobial Agents and Chemotherapy|August 30, 2008
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patientsJosé Moltó, José R Santos, Nuria Pérez-Alvarez, et al.
Vox Sanguinis|March 9, 2026
Pre-exposure prophylaxis use in blood donors in EnglandJaid Debrah, Claire Reynolds, Victoria Maddox, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Antiviral Therapy|May 4, 2005
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13)Alina Bergshoeff, David Burger, Corrien Verweij, et al.
British Journal of Clinical Pharmacology|November 28, 2015
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and childrenAlessandro Schipani, Henry Pertinez, Rachel Mlota, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 30, 2009
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic studySonia Rodríguez-Nóvoa, Pablo Labarga, Vincent Soriano, et al.
Journal of the International AIDS Society|November 14, 2014
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implantKimberly Scarsi, Mohammed Lamorde, Kristin Darin, et al.
Pageof 29